✦ LIBER ✦

PCN7 THE LIFETIME COST OF GEFITINIB (“IRESSA”) IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ Scribed by A Haiderali; W Chin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New perspectives in the management of no

✍ C. Manegold 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 280 KB

PD-157 Serum EGFR in patients with non-s

✍ Spreafico, A.; Gregorc, V.; Ludovini, V.; Pistola, L.; Amoroso, M.; Tofanetti, F 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

P-449 FDG-PET SCAN in the evaluation of

✍ Miwa, Toshiro; Kashii, Tatsuhiko; Oda, Hirofumi; Fujita, Tadashi; Fujishita, Tak 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 176 KB

‘Targeting’ the epidermal growth factor

✍ William Pao; Vincent A. Miller; Mark G. Kris 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 182 KB

PCN58 A COST UTILITY ANALYSIS OF ERLOTIN

✍ PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Activity of ZD1839 (Gefitinib, Iressa™)

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB